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ScienceDirectMacrocyclic structure and backbone N-methylation represent
characteristic features of peptidic natural products, which play
critical roles in their biological activity. Although natural
products have been the traditional source of such peptides,
recent developments in synthesizing natural product-like
macrocyclic peptides using reconstituted translation systems
have enabled us to construct vast trillion-member libraries of
non-standard macrocyclic peptides. In addition, a method for
displaying such libraries on their corresponding mRNA
templates allows us to rapidly screen them for potent ligands
against various drug targets. This review describes
methodologies for the ribosomal synthesis of novel natural
product-like macrocyclic peptides and their recent
applications in the discovery of bioactive molecules using in
vitro display technologies.
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Introduction
Throughout the years, investigations of various clinically
significant natural products have provided insight on
important structural features that are necessary to afford
high biological activity [1–3]. Amongst these features,
macrocyclization is arguably the most basic and important
structural property to confer, particularly in peptidic
natural products. To date there have been many reports
underlying the importance of having a cyclic structure
over a linear one, whether they be small molecules or
peptides [4]. The structural stability gained from macro-
cyclization allows peptides to spend more time in bio-
logically active conformations, therefore decreasing the
entropic cost upon binding their target [5]. Amide bonds
in such constrained cyclic peptides also become morewww.sciencedirect.com difficult to access by proteases resulting in greater serum
stability. In regards to passive membrane permeability, a
macrocyclic structure potentially increases the likelihood
of the formation of intramolecular hydrogen bonds which
can decrease interactions with water, thus increasing the
potential for membrane permeability [6].
Many natural product peptides also contain N-methyl
amino acids [7]. Similar to macrocyclization, N-methyla-
tion decreases conformational flexibility around the N-
methylated peptide bond through steric effects with its
neighboring amino acid side chains and stabilizes the
conformation via A1,3-like strain. N-methylation of the
peptide backbone also decreases the hydrogen bond
donating ability of the peptide bond to water molecules,
potentially improving membrane permeability. As with
most deviations from the 20 proteinogenic amino acids,
N-methylation also enhances the serum stability of such
peptides through decreased accessibility to proteases.
Taken together, the combination of macrocyclization
and backbone N-methylation of peptidic natural products
significantly improves their drug-like properties.
Unlike proteins that are synthesized by the translation
system consisting of the ribosome and translation factors,
peptidic natural products are often synthesized from large
multienzyme complexes, called nonribosomal peptide
synthetases [8] (NRPSs). These complexes work in con-
cert through various modules assigned to specific reac-
tions necessary for the synthesis of each individual amino
acid and their subsequent polymerization, modification
and cyclization. The engineering of these NRPSs for the
synthesis of diverse libraries is attractive yet scientifically
challenging and has met limited success in producing
libraries of diverse macrocyclic peptides due to their
mechanistic and structural complexity [9].
In contrast, recent advances in manipulating cell-free
translation systems [10] have given new opportunities
to construct vast libraries of macrocyclic peptides and to
screen for bioactive molecules by means of in vitro display
systems. This review will discuss concepts and recent
examples of novel macrocyclic peptides discovered by
these technologies.
Ribosomal synthesis of natural product-like
macrocyclic peptides
To synthesize macrocyclic peptides using the translation
machinery, the most basic approach is through disulfideCurrent Opinion in Chemical Biology 2015, 24:131–138
132 Omicsbonds between cysteine residues [11]. However, their
susceptibility to reduction in intracellular environments
makes them undesirable for some applications. There-
fore, methods of forming a non-reducible covalent bond
for cyclization through simple chemical post-translational
modifications have been devised. Methods of bridging
two primary amines between the N-terminus and a lysine
sidechain using disuccinimidyl glutarate (Figure 1a) or
the sulfhydryl group of two cysteine residues using
dibromoxylene (Figure 1b) have been used to success-
fully generate macrocyclic peptides [12,13]. A similar
method of producing bicyclic peptides via thioether-
crosslinking of three cysteine residues has been also
reported (Figure 1c) [14]. An advantage of these
methods is their applicability to the standard proteino-
genic amino acids. However, when more than two reac-
tive residues appear in the random regions of these
libraries, the crosslinking patterns become scrambled
potentially causing difficulty in deconvoluting the out-
come of selections based on such cyclization methods.
A technically more demanding method than the above,
but far more reliable for the construction of macrocyclic
peptides, is based on the concept of manipulating the
genetic code, known as genetic code reprogramming,Figure 1
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reassigned to nonproteinogenic amino acids. Two major
methodologies have been reported to date, both of which
utilize custom-made reconstituted translation systems.
One method takes advantage of the mischarging proper-
ties of aminoacyl-tRNA synthetases in the presence of
excess amounts of nonproteinogenic amino acids, yield-
ing the corresponding aminoacyl-tRNAs. Szostak et al.
reported a method of generating peptides containing 4-
selenalysine in the peptide chain followed by the se-
lective oxidation and concomitant elimination of the
seleno group to yield a dehydroalanine residue
(Figure 2a) [15]. Dehydroalanine then reacts with the
sulfhydryl group of cysteine via Michael addition to form
a thioether bond, giving rise to lanthionine-like macro-
cyclic peptides.
The other method involves ’flexible’ tRNA acylation
ribozymes, known as flexizymes [16–18], developed by
Suga et al., which facilitate the preparation of a wide array
of nonproteinogenic aminoacyl tRNAs with nearly unlim-
ited choice. The combination of a custom-made in vitro
translation system with flexizymes, referred to as the FIT
(Flexible In vitro Translation) system, allows the ribosomalCyclization additive
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Peptide cyclization methods made possible by genetic code reprogramming. (a) Aminoacyl-tRNA synthetase mischarging used to incorporate 4-
selenalysine to ultimately form a lanthionine bridge with a cysteine residue [15]. (b)–(e) Cyclization methods using the FIT system: (b) Incorporation
of vinylglycine to form a methyllanthionine bridge with a cysteine residue [19]. (c) Peptide translation initiated with N-benzylamine and the
incorporation of hydroxytryptophan to create a fluorogenic benzoxazole bridge [20]. (d) Incorporation of glycolic acid after cysteine and proline
residues results in spontaneous conversion to diketopiperdine. The amino terminus produced by the subsequent treatment with peptide
deformylase and methionine aminopeptidase reacts with the diketopiperidine to form a backbone cyclized peptide [21–23]. (e) Peptide translation
initiated with an N-chloroacetyl amino acid to form thioether bonds with cysteine residues [24].synthesis of macrocyclic peptides using nonproteinogenic
amino acids capable of crosslinking with other proteino-
genic or nonproteinogenic residues (Figure 3a). The FIT
system allows for a wide variety of cyclization methods, for
instance, methyllanthionine-like macrocyclic peptides can
be synthesized through the incorporation of vinylglycine
which is thermally isomerized to dehydrobutyrine which
can then form a thioether bond with cysteine residueswww.sciencedirect.com (Figure 2b) [19]. Translation of peptides containing a
benzylamine group designated by the N-terminal initiating
amino acid and a downstream 5-hydroxytryptophan is a
unique method of mild oxidative macrocyclization forming
a fluorogenic indole linkage (Figure 2c) [20]. Moreover,
ribosomal synthesis of head-to-tail linked peptides can also
be produced through the C-terminal Cys-Pro-HOG (glycolic
acid) sequence or programmed peptidyl-tRNA drop-offCurrent Opinion in Chemical Biology 2015, 24:131–138
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The RaPID and TRAP systems. (a) Nonproteinogenic amino acids are charged on to tRNAs by flexizymes. (b) A DNA library is transcribed and the
mRNA is attached to puromycin and then translated (attachment of puromycin differs between RaPID and TRAP [42,52]). (c) Unwanted mRNA-
peptide fusions are removed by counter selections. (d) Target protein binding mRNA-peptide fusions are isolated and amplified for iterative rounds
of selection or for sequencing.containing the C-terminal Cys-Pro sequence (Figure 2d)
[21–23]. In both cases, the C-terminal ester bond accelerates
the self-rearrangement of N ! S migration to form a C-
terminal diketopiperadine-thioester, eventually yielding
backbone-cyclized monocyclic or disulfide-bridged bicyclic
peptides.
The most convenient and reliable method of cyclization
has been through the translation of peptides with an N-
chloroacetyl-amino acid initiator that can react with a
downstream cysteine (Figure 2e) [24]. The advantage of
this method is the spontaneous and selective thioether
bond formation between the N-terminal chloroacetyl
group and the sulfhydryl group of the closest cysteine
residue [25]. A single exception is that a cysteine residueCurrent Opinion in Chemical Biology 2015, 24:131–138 adjacent to the N-chloroacetyl-amino acid cannot react
with the chloroacetyl group due to ring constraint, thus
leaving a free sulfhydryl group at this position. However,
this selectivity turns out be a convenient way to translate
fused-bicyclic peptides, having a thioether (sulfide) bond
between the N-terminus and the second cysteine and a
disulfide bond between the first and third cysteine resi-
dues. Importantly, it has been demonstrated that the FIT
system facilitates the translation of peptides containing D-
amino acids [26], N-methyl-amino acids [27], N-alkylgly-
cines [28], and those with noncanonical sidechains [29–33].
Thus, a variety of peptide libraries can be readily prepared
in an mRNA-encoded manner, leading to the development
of a display-based platform technology for the discovery of
bioactive natural product-like macrocyclic peptides.www.sciencedirect.com
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macrocyclic peptides from vast libraries
The methods discussed above can be readily combined
with appropriate display platforms to screen for active
ligands against therapeutic targets. A recent and elegant
method reported by Heinis et al. [14] has successfully
produced potent thioether-linked bicyclic peptide inhibi-
tors against human proteases (IC50 = 20–50 nM) through
phage display. It should be noted, however, that although
the phage display selection has yielded potent inhibitors
(IC50 < 100 nM) for certain targets from an initial selec-
tion, it occasionally yields less potent inhibitors
(IC50 > 1 mM) and thus reconstruction of a focused
library based on previously selected peptide sequences
becomes necessary to reselect for more potent inhibitors.
This is attributed to the sequence diversity of bacterial
phage display libraries, often being <1010, resulting from
the transformation efficiency of phages to the host cells
[34]. mRNA display, where the C-terminal residue of aFigure 4
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www.sciencedirect.com peptide is fused with puromycin-linked mRNA [35],
requires no transformation or living organisms and thus
has diversities in the trillions. In addition, genetic code
reprogramming is far easier to perform in vitro rather than
in bacteriophage or living organisms, even though a
technology allowing for the incorporation of one or two
proteinogenic amino acids into phage displayed peptides
has been reported [36].
To date many successful selections of macrocyclic pep-
tides using mRNA display or its variants have been
reported [37]. The Szostak group has reported two
examples of selections discovering macrocyclic peptides
against thrombin [12] (KD = 1.5 nM) and sortase A [38
]
(KD = 3 mM), where the former selection used a post-
translational thioether-crosslinking method while the lat-
ter used the lanthionine-like intramolecular cyclization
method described earlier. Roberts et al. reported the
selection of macrocyclic peptides against Gai1 whichCurrent Opinion in Chemical Biology
elements highlighted in yellow). (a) Structure of the macrocyclic
in an inward open conformation [46]. (c) Structure of S2iL5 which
various interactions involved in the inhibition of SIRT2 by S2iL5 [48].
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136 Omicswere cyclized via an N-hydroxysuccinamide-activated
crosslinking reagent between the N-terminal amino group
in the mainchain and an e-amino sidechain of a lysine
residue [39] (KD = 2.1 nM). It should be noted that this
anti-Gai1 peptide selection involved translation of a
peptide library with N-methylphenylalanine using the
amber codon suppression method, but no sequences
containing N-methylphenylalanine were discovered [40].
The FIT system has also been coupled with mRNA dis-
play, referred to as the RaPID (Random non-standard
Peptides Integrated Discovery) system (Figure 3)
[41,42], which has produced bioactive macrocyclic pep-
tides against various targets [43–45,47,49]. By initiating
peptide translation with N-chloroacetyl-L-amino acids or D-
amino acids, thioether macrocyclized peptide libraries can
be translated and covalently displayed on their correspond-
ing mRNAs. For instance, the RaPID system has been
applied for the selection of highly isoform-selective inhibi-
tors against the protein kinase Akt2 [44] (IC50 = 110 nM
and >250-fold and 40-fold higher IC50 for Akt1 and Akt2,
respectively) and a histone deacetylase SIRT2
(Figure 4a,b) [43,48] (IC50 = 3 nM and 10-fold and 100-
fold higher IC50 against SIRT1 and SIRT3, respectively;
an X-ray co-crystal structure of SIRT2-macrocyclic peptide
is available). Inhibitory macrocyclic peptides were also
discovered against a bacterial membrane drug-transporter
MATE [45,49,50] (multidrug and toxin extrusion) protein
and three macrocyclic peptides were co-crystalized with
MATE, revealing the first example of a three-dimensional
structure of macrocyclic peptides isolated by the RaPID
system. Two of such peptides bear a lariat structure con-
sisting of an N-terminal ‘mini-cycle’ followed by a C-
terminal ‘tail’. Interestingly, the crystal structures show
that the mini-cycle was buried deep into the cleft of the
transporter with the tail region occupying the rest of the
cleft. The level of target accommodation observed in this
X-ray structure demonstrates how the macrocyclic portion
fits to the drug-transporting channel, indicating the benefit
of using trillion member macrocyclic peptide libraries.
More recently, macrocyclic peptide inhibitors were also
selected against a eukaryotic ABC-drug transporter
(Figure 4c,d) [46] (IC50 = 65 nM); the X-ray structural
analysis of one of the macrocycles has revealed its distinct
structure from anti-MATE macrocyclic peptides and the
mechanism for its inhibitory activity.
A major strength of the RaPID system is the ability of
expressing N-methyl-macrocyclic peptides and the selec-
tion of active species. To date, two examples of such
inhibitors have been published: one against E6AP [47],
a HECT domain E3 ubiquitin ligase, and another against
VEGFR2 [51], a human membrane protein growth factor
receptor (in this work an updated method of RaPID,
referred to as TRAP display [52], is used). Both cases
have given potent inhibitors (KD = 0.6 nM and 33 nM for
E6AP and VEGFR2, respectively).Current Opinion in Chemical Biology 2015, 24:131–138 Future directions
Manipulations of the translation system to synthesize vast
libraries of macrocyclic peptides with similar features
seen in naturally occurring ones combined with screening
via mRNA display methods have shown great potential
for accelerating the discovery of bioactive natural pro-
duct-like macrocycles. Because of the high inhibitory
activity and specificity of the selected molecules, these
technologies seem to be excellent platforms for the dis-
covery of drug leads against enzymes and proteins
involved in protein–protein interactions. In terms of drug
development, these technologies have solved issues of
proteolytic instability and insufficient potency of
traditional peptidic drugs, and therefore are suitable for
developing drug leads for extracellular targets, which can
be delivered via intravenous administration or other
related methods. However, some issues such as insuffi-
cient cell-membrane permeability for targeting intra-
cellular proteins and oral bioavailability of selected
macrocyclic peptides still remain to be resolved. In the
future, therefore, it will be required to improve this
technology by adding more natural product-like struc-
tures, for example, including heterocycles in the back-
bone, or an appropriate selective pressure that enables us
to discover macrocyclic peptides with better drug-like
properties.
Acknowledgements
We thank Dr. Christopher J Hipolito, Prof. Osamu Nureki’s group at the
University of Tokyo, and Prof. Hiroaki Kato’s group at Kyoto University for
the collaborations related to this work. This work was supported by the
Platform for Drug Discovery, Informatics, and Structural Life Science from
MEXT, Japan to HS.
References and recommended reading
Papers of particular interest, published within the period of review,
have been highlighted as:
 of special interest
 of outstanding interest
1. Driggers EM, Hale SP, Lee J, Terrett NK: The exploration of
macrocycles for drug discovery — an underexploited
structural class. Nat Rev Drug Discov 2008, 7:608-624.
2. Walsh CT: The chemical versatility of natural-product
assembly lines. Acc Chem Res 2008, 41:4-10.
3. Craik DJ, Fairlie DP, Liras S, Price D: The future of peptide-based
drugs. Chem Biol Drug Des 2013, 81:136-147.
4. Dinsmore CJ, Bogusky MJ, Culberson JC, Bergman JM,
Homnick CF, Zartman CB, Mosser SD, Schaber MD,
Robinson RG, Koblan KS et al.: Conformational restriction of
flexible ligands guided by the transferred noe experiment:
potent macrocyclic inhibitors of farnesyltransferase. J Am
Chem Soc 2001, 123:2107-2108.
5. Khan AR, Parrish JC, Fraser ME, Smith WW, Bartlett PA,
James MN: Lowering the entropic barrier for binding
conformationally flexible inhibitors to enzymes. Biochemistry
1998, 37:16839-16845.
6. Rezai T, Yu B, Millhauser GL, Jacobson MP, Lokey RS: Testing
the conformational hypothesis of passive membrane
permeability using synthetic cyclic peptide diastereomers. J
Am Chem Soc 2006, 128:2510-2511.www.sciencedirect.com
In vitro displays for the screening of vast libraries Bashiruddin and Suga 1377. Chatterjee J, Gilon C, Hoffman A, Kessler H: N-methylation of
peptides: a new perspective in medicinal chemistry. Acc Chem
Res 2008, 41:1331-1342.
8. Fischbach MA, Walsh CT: Assembly-line enzymology for
polyketide and nonribosomal peptide antibiotics: logic,
machinery, and mechanisms. Chem Rev 2006, 106:3468-3496.
9. Weissman KJ, Mu¨ller R: Protein–protein interactions in
multienzyme megasynthetases. ChemBioChem 2008, 9:826-
848.
10. Shimizu Y, Inoue A, Tomari Y, Suzuki T, Yokogawa T, Nishikawa K,
Ueda T: Cell-free translation reconstituted with purified
components. Nat Biotechnol 2001, 19:751-755.
11. Raffler NA, Schneider-Mergener J, Famulok M: A novel class of
small functional peptides that bind and inhibit human alpha-
thrombin isolated by mRNA display. Chem Biol 2003, 10:69-79.
12. Millward SW, Takahashi TT, Roberts RW: A general route for
post-translational cyclization of mRNA display libraries. J Am
Chem Soc 2005, 127:14142-14143.
13. Schlippe YV, Hartman MC, Josephson K, Szostak JW: In vitro
selection of highly modified cyclic peptides that act as tight
binding inhibitors. J Am Chem Soc 2012, 134:10469-10477.
14.

Heinis C, Rutherford T, Freund S, Winter G: Phage-encoded
combinatorial chemical libraries based on bicyclic peptides.
Nat Chem Biol 2009, 5:502-507.
In this study, phage displayed peptides were bicyclized with tris-bromo-
methyl benzene and used to select for kallikrein inhibiting peptides. Two
iterative selections were required, one for each cycle, and resulted in a
bicyclic peptide with 1.5 nM Ki.
15. Seebeck FP, Ricardo A, Szostak JW: Artificial lantipeptides from
in vitro translations. Chem Commun (Camb) 2011, 47:6141-
6143.
16. Goto Y, Katoh T, Suga H: Flexizymes for genetic code
reprogramming. Nat Protoc 2011, 6:779-790.
17. Murakami H, Ohta A, Ashigai H, Suga H: A highly flexible tRNA
acylation method for non-natural polypeptide synthesis. Nat
Methods 2006, 3:357-359.
18. Passioura T, Suga H: Flexizymes, their evolutionary history and
diverse utilities. Top Curr Chem 2014, 344:331-345.
19. Goto Y, Iwasaki K, Torikai K, Murakami H, Suga H: Ribosomal
synthesis of dehydrobutyrine- and methyllanthionine-
containing peptides. Chem Commun (Camb) 2009, 23:3419-
3421.
20. Yamagishi Y, Ashigai H, Goto Y, Murakami H, Suga H: Ribosomal
synthesis of cyclic peptides with a fluorogenic oxidative
coupling reaction. ChemBioChem 2009, 10:1469-1472.
21. Kawakami T, Ohta A, Ohuchi M, Ashigai H, Murakami H, Suga H:
Diverse backbone-cyclized peptides via codon
reprogramming. Nat Chem Biol 2009, 5:888-890.
22. Ohshiro Y, Nakajima E, Goto Y, Fuse S, Takahashi T, Doi T,
Suga H: Ribosomal synthesis of backbone-macrocyclic
peptides containing g-amino acids. ChemBioChem 2011,
12:1183-1187.
23. Kang TJ, Hayashi Y, Suga H: Synthesis of the backbone cyclic
peptide sunflower trypsin inhibitor-1 promoted by the induced
peptidyl-tRNA drop-off. Angew Chem Int Ed Engl 2011, 50:2159-
2161.
24. Goto Y, Ohta A, Sako Y, Yamagishi Y, Murakami H, Suga H:
Reprogramming the translation initiation for the synthesis of
physiologically stable cyclic peptides. ACS Chem Biol 2008,
3:120-129.
25. Iwasaki K, Goto Y, Katoh T, Suga H: Selective thioether
macrocyclization of peptides having the N-terminal 2-
chloroacetyl group and competing two or three cysteine
residues in translation (10 (2012) 5783). Org Biomol Chem 2012,
10:9748.
26. Fujino T, Goto Y, Suga H, Murakami H: Reevaluation of the D-
amino acid compatibility with the elongation event in
translation. J Am Chem Soc 2013, 135:1830-1837.www.sciencedirect.com 27. Kawakami T, Murakami H, Suga H: Messenger RNA-
programmed incorporation of multiple N-methyl-amino acids
into linear and cyclic peptides. Chem Biol 2008, 15:32-42.
28. Kawakami T, Murakami H, Suga H: Ribosomal synthesis of
polypeptoids and peptoid-peptide hybrids. J Am Chem Soc
2008, 130:16861-16863.
29. Goto Y, Murakami H, Suga H:: Initiating translation with D-amino
acids. RNA 2008, 14:1390-1398.
30. Sako Y, Morimoto J, Murakami H, Suga H: Ribosomal synthesis
of bicyclic peptides via two orthogonal inter-side-chain
reactions. J Am Chem Soc 2008, 130:7232-7234.
31. Nakajima E, Goto Y, Sako Y, Murakami H, Suga H: Ribosomal
synthesis of peptides with C-terminal lactams, thiolactones,
and alkylamides. ChemBioChem 2009, 10:1186-1192.
32. Sako Y, Goto Y, Murakami H, Suga H: Ribosomal synthesis of
peptidase-resistant peptides closed by a non-reducible inter-
sidechain bond. ACS Chem Biol 2008, 3:241-249.
33. Goto Y, Suga H: Translation initiation with initiator tRNA
charged with exotic peptides. J Am Chem Soc 2009, 131:5040-
5041.
34. Derda R, Tang SK, Li SC, Ng S, Matochko W, Jafari MR: Diversity
of phage-displayed libraries of peptides during panning and
amplification. Molecules 2011, 16:1776-1803.
35. Roberts RW, Szostak JW: RNA-peptide fusions for the in vitro
selection of peptides and proteins. Proc Natl Acad Sci U S A
1997, 94:12297-12302.
36. Tian F, Tsao ML, Schultz PG: A phage display system with
unnatural amino acids. J Am Chem Soc 2004, 126:15962-15963.
37. Ito K, Passioura T, Suga H: Technologies for the synthesis of
mRNA-encoding libraries and discovery of bioactive natural
product-inspired non-traditional macrocyclic peptides.
Molecules 2013, 18:3502-3528.
38.

Hofmann FT, Szostak JW, Seebeck FP:: In vitro selection of
functional lantipeptides. J Am Chem Soc 2012, 134:8038-8041.
The only example of an in vitro selection for lanthionine containing
peptides. Although the selected lantipeptides had modest binding affi-
nity, it was shown that the lanthionine moiety was required for binding.
39. Millward SW, Fiacco S, Austin RJ, Roberts RW: Design of cyclic
peptides that bind protein surfaces with antibody-like affinity.
ACS Chem Biol 2007, 2:625-634.
40. Frankel A, Millward SW, Roberts RW: Encodamers: unnatural
peptide oligomers encoded in RNA. Chem Biol 2003, 10:1043-
1050.
41. Hipolito CJ, Suga H: Ribosomal production and in vitro
selection of natural product-like peptidomimetics: the FIT and
RaPID systems. Curr Opin Chem Biol 2012, 16:196-203.
42. Passioura T, Suga H: Flexizyme-mediated genetic
reprogramming as a tool for noncanonical peptide synthesis
and drug discovery. Chemistry 2013, 19:6530-6536.
43.

Morimoto J, Hayashi Y, Suga H: Discovery of macrocyclic
peptides armed with a mechanism-based warhead: isoform-
selective inhibition of human deacetylase SIRT2. Angew Chem
Int Ed Engl 2012, 51:3423-3427.
A lysine analog, e-N-trifluoroacetyl lysine, known to inhibit SIRT2 was
incorporated into peptides as a ‘warhead’ to direct the selection of
inhibitory macrocyclic peptides. Details of the inhibitory mechanism is
discussed herein.
44. Hayashi Y, Morimoto J, Suga H: In vitro selection of anti-Akt2
thioether-macrocyclic peptides leading to isoform-selective
inhibitors. ACS Chem Biol 2012, 7:607-613.
45. Hipolito C, Tanaka Y, Katoh T, Nureki O, Suga H: In vitro selection
of cyclic peptides for cocrystallization with a multidrug and
toxic compound extrusion protein. Biopolymers 2013, 100:238-
239.
46. Kodan A, Yamaguchi T, Nakatsu T, Sakiyama K, Hipolito CJ,
Fujioka A, Hirokane R, Ikeguchi K, Watanabe B, Hiratake J et al.:
Structural basis for gating mechanisms of a eukaryoticCurrent Opinion in Chemical Biology 2015, 24:131–138
138 OmicsP-glycoprotein homolog. Proc Natl Acad Sci U S A 2014,
111:4049-4054.
47.

Yamagishi Y, Shoji I, Miyagawa S, Kawakami T, Katoh T, Goto Y,
Suga H: Natural product-like macrocyclic N-methyl-peptide
inhibitors against a ubiquitin ligase uncovered from a
ribosome-expressed de novo library. Chem Biol 2011, 18:1562-
1570.
To date, this selection has produced macrocyclic peptides with the most
N-methyl amino acids per peptide (up to 5) consisting of N-methyl-
glycine, N-methyl-alanine, N-methyl-serine and N-methyl-phenylalanine.
Several multiple N-methylated macrocyclic peptides exhibited low to
subnanomolar binding affinites as well as some in vitro inhibitory acitivity.
48. Yamagata K, Goto Y, Nishimasu H, Morimoto J, Ishitani R,
Dohmae N, Takeda N, Nagai R, Komuro I, Suga H et al.: Structural
basis for potent inhibition of SIRT2 deacetylase by a
macrocyclic peptide inducing dynamic structural change.
Structure 2014, 22:345-352.
49. Hipolito CJ, Tanaka Y, Katoh T, Nureki O, Suga H: A macrocyclic
peptide that serves as a cocrystallization ligand and inhibitsCurrent Opinion in Chemical Biology 2015, 24:131–138 the function of a MATE family transporter. Molecules 2013,
18:10514-10530.
50.

Tanaka Y, Hipolito CJ, Maturana AD, Ito K, Kuroda T, Higuchi T,
Katoh T, Kato HE, Hattori M, Kumazaki K et al.: Structural basis
for the drug extrusion mechanism by a MATE multidrug
transporter. Nature 2013, 496:247-251.
The RaPID system was used to select for macrocyclic peptide cocrys-
tallization ligands with inhibitory activity. Peptides with macrocyclic and
‘lariat’ structures were discovered and their binding mechanisms are
discussed.
51. Kawakami T, Ishizawa T, Fujino T, Reid PC, Suga H, Murakami H:
In vitro selection of multiple libraries created by genetic code
reprogramming to discover macrocyclic peptides that
antagonize VEGFR2 activity in living cells. ACS Chem Biol 2013,
8:1205-1214.
52. Ishizawa T, Kawakami T, Reid PC, Murakami H: TRAP display: a
high-speed selection method for the generation of functional
polypeptides. J Am Chem Soc 2013, 135:5433-5440.www.sciencedirect.com
